Chronic kidney disease screening and renoprotection in type 2 diabetes

Emamnuel I. Agaba*, F. H. Puepet, S. O. Ugoya, P. A. Agaba, R. Adabe, M. Duguru, A. I. Rowland

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    2 Citations (Scopus)


    Background: Type 2 diabetes (T2D) is a major cause of chronic kidney disease. Control of hypertension and the use of angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II receptor blockers especially in those with proteinuria have been shown to protect against chronic kidney disease and delay its progression to kidney failure. Methods: We reviewed the medical records of 169 patients at 12 months with a view of auditing the screening for chronic kidney disease and the use of renoprotective measures. Results: Urinalysis was done in 49.1% and serum creatinine in 50.3%. No patient had glomerular filtration rate estimated. Seventy nine (67.6%) of the hypertensive patients were on anti-hypertensives. ACEI was used in 49 (45.8%) of these patients BP control was optimal in 29.1%. Conclusion: There is poor adherence to guidelines on chronic kidney disease screening and renoprotection in T2D.

    Original languageEnglish
    Pages (from-to)52-54
    Number of pages3
    JournalAnnals of African Medicine
    Issue number1
    Publication statusPublished - 2009


    • Chronic kidney disease
    • Diabetes
    • Renoprotection


    Dive into the research topics of 'Chronic kidney disease screening and renoprotection in type 2 diabetes'. Together they form a unique fingerprint.

    Cite this